Safety and Efficacy of Tolvaptan for the Prevention of Contrast-Induced Acute Kidney Injury in Patients with Heart Failure and Chronic Kidney Disease.
Journal:
Kidney diseases (Basel, Switzerland)
Published Date:
Nov 29, 2018
Abstract
BACKGROUND: Tolvaptan is a promising drug for the prevention of contrast-induced acute kidney injury (CI-AKI) because it induces aquaresis without adversely affecting renal hemodynamics. CI-AKI is a major cause of acute renal failure associated with increased morbidity and mortality.
Authors
Keywords
No keywords available for this article.